The design and selection of Cytotoxic Payloads of ADCs are crucial for maximizing therapeutic efficacy and minimizing side effects. Researchers focus on optimizing these payloads to enhance stability, potency, and selective tumor cell lysis, thereby advancing the development of next-generation cancer therapies with improved safety profiles and treatment outcomes.